KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 3

The efficacy of divalent iron preparations with and withoutzinc in the treatment of iron deficiency anemia

Özcan Bör
Yeter Düzenli Kar
Zeynep Canan Özdemir
Yasemin Ersozlu
Hatice Burcu Çağlar
Sayfa
511–515
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: We found that FeS and Fe2+-Zn preparations had similar effects on hematologic parameters and iron status in IDA; however, the treatment period in patients who received Fe2+-Zn was longer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Iron deficiency anemia (IDA) is the most frequently detected cause of anemia in Turkey and worldwide.
📊
Temel Bulgular & Veri:In this study, we investigated the efficacy of the iron preparations of ferrous sulfate (group FeS, Fe2+) and ferrous fumarate combined with Zn (group Fe2+-Zn) in the treatment of IDA.
💡
Sonuç & Katkı:Conclusion: We found that FeS and Fe2+-Zn preparations had similar effects on hematologic parameters and iron status in IDA; however, the treatment period in patients who received Fe2+-Zn was longer.
🔬Tür:Araştırma Makalesi
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Iron deficiency anemia (IDA) is the most frequently detected cause of anemia in Turkey and worldwide. In this study, we investigated the efficacy of the iron preparations of ferrous sulfate (group FeS, Fe2+) and ferrous fumarate combined with Zn (group Fe2+-Zn) in the treatment of IDA. Materials and Methods: Seventy children receiving FeS and 24 children receiving Fe2+-Zn due to IDA between June 2018 and January 2019 were included in the study. The Hb, MCV, MCH, RBC, transferrin saturation, ferritin levels before treatment and in the 1st and 3rd months after treatment, period of drug use, and the frequency of gastrointestinal adverse effects in the two groups were investigated. Results: There was no difference between the two groups regarding age and sex. The mean drug dose in FeS group was 4.01±0.98 mg/kg/day and 4.12±0.06 mg/kg/day in the Fe2+-Zn group (p>0.05). The Hb, MCV, MCH, RBC, transferrin saturation, and ferritin levels in both groups in the 1st and 3rd months after treatment were found significantly higher compared with the levels before treatment. No difference was detected between the two groups for the same parameters before treatment, and in the 1st and 3rd months after treatment (p>0.05, for all). The period of drug use in Fe2+-Zn group (median:4.5 months) was longer than in the FeS group (median:4 months) (p0.05). Conclusion: We found that FeS and Fe2+-Zn preparations had similar effects on hematologic parameters and iron status in IDA; however, the treatment period in patients who received Fe2+-Zn was longer.

🔖

Bu Makaleye Atıf Yap

Bör, Ö., Kar, Y. D., Özdemir, Z. C., Ersozlu, Y., Çağlar, H. B. (2022). The efficacy of divalent iron preparations with and withoutzinc in the treatment of iron deficiency anemia. Annals of Medical Research, Cilt: 28 - Sayı: 3, 511–515. https://ajindex.com/articles/445869

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Bailey RL, West KP Jr, Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr Metab 2015;66:22-33
  2. Wilson DB. Disorders of Iron Metabolism and Sideroblastic Anemia. In: Nathan DG, Orkin SH, Gingsburg D, Look TA, editors. Nathan and Oski’s Hematology of Infancy and Childhood. 6th edition. Philadelphia: WB Saunders Company 2009;522-42
  3. Freire WB. Strategies of the Pan American Health Organization/World Health Organization for the control of iron deficiency in Latin America. Nutr Reviews 1997;55:183-8
  4. WHO. Results and discussion. In: B de Benoist, E Mclean, I Egli, M Cogswell (eds). Worldwide Prevalence of Anemia 1993-2005: WHO Global Database on Anemia. WHO: Geneva, Switzerland; 2008
  5. Black MM. Zinc deficiency and child development. Am J Clin Nutr 1998;68:464-9
  6. Cakmak D, Kalaycı M, Ekiz H, et al. Zinc deficiency as a practical problem in plant and human nutrition in Turkey: A NATO Science for Stability project. Field Crops Research 1999;60:175-88
  7. Wetherilt H, Ackurt F, Brubacher G, et al. Blood vitamin and mineral levels in 7-17 years old Turkish children. Int J Vitam Nutr Res 1992;62:21-9
  8. David BM. Trace elements. In: Carl AB, Edward RA, editors. Tietz Textbook of Clinical Chemistry. 3rd edition. Philadelphia: WB Saunders Company; 1999;1029-55
  9. Ece A, Uyanik BS, Iscan A, et al. Increased serum copper and decreased serum zinc levels in children with iron deficiency anemia. Biol Trace Element Res 1997;59:31-9
  10. Bjørklund G, Aaseth J, Skalny AV, et al. Interactions of iron with manganese, zinc, chromium, and selenium as related to prophylaxis and treatment of iron deficiency. J Trace Elem Med Biol 2017;41:41-53
  11. Chang S, El Arifeen S, Bari S, et al. Supplementing iron and zinc: double blind, randomized evaluation of separate or combined delivery. Eur J Clin Nutr 2010;64:153-60
  12. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: World Health Organization; 2011. Available from:(WHO/ NMH/NHD/MNM/11.1) http://www.who.int/vmnis/ indicators/haemoglobin
  13. WHO, UNICEF, UNU. Iron deficiency anaemia: assessment, prevention and control, a guide for programme managers. Geneva, World Health Organization, 2001; WHO/ NHD/01.3.Available from: www.who.int/./en/ida_assessment_prevention_ control.pdf 14. Powers JM, Buchanan GR, Adix L, et al. Effect of lowdose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional